Journal article
In-hospital initiation of sodium-glucose co-transporter-2 inhibitors in patients with acute heart failure
Abstract
Sodium-glucose cotransporter-2 (SGLT2) inhibitors provide cardiovascular and kidney benefits to patients with heart failure (HF) and/or chronic kidney disease (CKD), regardless of diabetes status and left ventricular ejection fraction (LVEF). Despite robust data demonstrating the efficacy of SGLT-2 inhibitors in both ambulatory and hospital settings, real-world evidence suggests slow and varied adoption of SGLT2 inhibitors among patients …
Authors
Arshad MS; Jamil A; Greene SJ; Van Spall HGC; Fonarow GC; Butler J; Khan MS
Journal
Heart Failure Reviews, Vol. 30, No. 1, pp. 89–101
Publisher
Springer Nature
Publication Date
1 2025
DOI
10.1007/s10741-024-10446-2
ISSN
1382-4147